TreeFrog Therapeutics
PrivateLast Round
Debt
May 27, 2025
Total Funding Raised
$119.94M
Company Overview
TreeFrog Therapeutics operates in Healthcare & Life Sciences and is based in Pessac. Its latest recorded funding round was a Debt round in May 2025.
TreeFrog Therapeutics is a biotechnology company that develops a proprietary technology platform for the mass production and differentiation of stem cells to enable safe and affordable cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TreeFrog Therapeutics Comparables
Compare TreeFrog Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PBS Biotech | 77% | |
| Cellevate AB | 76% | |
| Cynata Therapeutics Limited | 73% |
For institutional investors. Book with your work email.
TreeFrog Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | May 27, 2025 | ||||
| Corporate Funding | Apr 23, 2024 | ||||
| Series B | Sep 13, 2021 | ||||
| Grant | Sep 5, 2019 | ||||
| Series A | May 13, 2019 | ||||
Grant | Mar 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TreeFrog Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Leonard Green & Partners | Series B |
| European Innovation Council Fund | Grant |
| European Commission | Grant |
| Ministry of Higher Education and Research | Grant |
| European Investment Bank Group | Debt |
| Aquiti Gestion | Series A, Seed |
| Galia Gestion | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Stem cell encapsulator moves from R&D to GMP manufacturing.
- Oct 1, 2025
Collaborating with Vertex Pharmaceuticals on C-STEM technology for diabetes treatment.
For institutional investors. Book with your work email.
TreeFrog Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TreeFrog Therapeutics's valuation, stock price, and market status.
Is TreeFrog Therapeutics a public or private company?
TreeFrog Therapeutics is a private company.
What is the current stock price of TreeFrog Therapeutics?
TreeFrog Therapeutics is a private company, so its shares have no public market price. Caplight tracks TreeFrog Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TreeFrog Therapeutics worth (valuation)?
Valuation information for TreeFrog Therapeutics is not publicly available.
Can I buy TreeFrog Therapeutics stock?
TreeFrog Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TreeFrog Therapeutics's last funding round?
TreeFrog Therapeutics's most recent funding round was Debt on May 27, 2025.
Who are the main investors in TreeFrog Therapeutics?
Key investors in TreeFrog Therapeutics include XAnge, Bpifrance.
Will TreeFrog Therapeutics IPO soon?
No public IPO plans have been announced for TreeFrog Therapeutics.
How can I track TreeFrog Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in TreeFrog Therapeutics's shares on secondary markets.